RT Journal Article
SR Electronic
T1 Oxidative Metabolism of Monensin in Rat Liver Microsomes and Interactions with Tiamulin and Other Chemotherapeutic Agents: Evidence for the Involvement of Cytochrome P-450 3A Subfamily
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 1039
OP 1044
VO 27
IS 9
A1 Carlo Nebbia
A1 Luciano Ceppa
A1 Mauro Dacasto
A1 Monica Carletti
A1 Carlo Nachtmann
YR 1999
UL http://dmd.aspetjournals.org/content/27/9/1039.abstract
AB Monensin (MON) is an ionophore antibiotic widely used in veterinary practice as a coccidiostatic or a growth promoter. The aims of this study were to characterize the P-450 isoenzyme(s) involved in the biotransformation of the ionophore and to investigate how this process may be affected by tiamulin and other chemotherapeutic agents known to produce toxic interactions with MON when administered concurrently in vivo. In liver microsomes from untreated rats (UT) or from rats pretreated, respectively, with ethanol (ETOH), β-naphthoflavone (βNAF), phenobarbital (PB), pregnenolone 16α-carbonitrile (PCN), or dexamethasone (DEX), the rate of MON O-demethylation was the following: DEX > PCN > PB ≫ UT = ETOH > βNAF; similar results were obtained by measuring total MON metabolism. In addition, the extent of triacetyloleandomycin-mediated P-450 complexes was greatly reduced by the prior addition of 100 μM MON. In DEX-treated microsomes, MON O-demethylation was found to fit monophasic Michaelis-Menten kinetics (KM = 67.6 ± 0.01 μM;Vmax = 4.75 ± 0.76 nmol/min/mg protein). Tiamulin markedly inhibited this activity in an apparent competitive manner, with a calculated Ki(Dixon plot) of 8.2 μM and an IC50 of about 25 μM. At the latter concentration, only ketoconazole or metyrapone, which can bind P-450 3A, inhibited MON O-demethylase to a greater extent than tiamulin, whereas α-naphthoflavone, chloramphenicol, or sulphametasine was less effective. These results suggest that P-450 3A plays an important role in the oxidative metabolism of MON and that compounds capable of binding or inhibiting this isoenzyme could be expected to give rise to toxic interactions with the ionophore. The American Society for Pharmacology and Experimental Therapeutics